Who Supplies Folic to India from GREECE

Importing finished pharmaceutical formulations containing Folic acid (HS Code 30049099) into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The foreign manufacturer must obtain a valid manufacturing or wholesale drug license from the country of origin. An Importer License from the Directorate General of Foreign Trade (DGFT) is mandatory. The product must be registered with the Central Drugs Standard Control Organisation (CDSCO) in India, which involves submitting Form 40 or 41, along with a No Objection Certificate (NOC) from the manufacturer. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for import drug registration varies but typically ranges from 6 to 12 months. Specific requirements for Folic acid formulations include detailed product information, manufacturing process details, and evidence of safety and efficacy.

Imported Folic acid formulations must undergo quality testing at CDSCO-approved laboratories in India. Batch-wise testing is required, with each batch accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) Zone IV guidelines, must be provided to demonstrate product stability under Indian climatic conditions. Port inspection by customs drug inspectors ensures that imported products meet safety and quality standards. If a batch fails quality testing, it may be rejected, leading to re-exportation or destruction, depending on the circumstances.

Between 2024 and 2026, the CDSCO has implemented regulatory updates affecting the import of finished pharmaceutical formulations, including Folic acid products. The Production Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Greece have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may simplify the import process for Greek manufacturers.

India imports finished Folic acid formulations to meet the demand for specific dosage forms and branded products not available domestically. The domestic market for Folic acid formulations is substantial, with a total export market of $56.1 million across 693 exporters to 148 countries. Ajanta Pharma Limited is a significant importer, indicating a robust demand for such products. The need for specialized formulations and patented products contributes to the reliance on imports to fulfill market requirements.

The Basic Customs Duty (BCD) for HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable. Additionally, a Social Welfare Surcharge (SWS) of 10% is levied. The total landed duty, including all applicable taxes and surcharges, is approximately 23.6% of the Cost, Insurance, and Freight (CIF) value. There are no specific exemptions or concessional rates for imports from Greece under this HS code.

India sources Folic acid formulations from Greece due to the country's competitive advantages, including patented formulations, specialized dosage forms, and high-quality manufacturing standards. Greek manufacturers like Privaposervices GmbH offer products that meet international quality standards, making them attractive to Indian buyers. While other suppliers such as China, Germany, and the United States also export Folic acid formulations to India, Greece's reputation for quality and compliance with regulatory standards enhances its position in the Indian market.

India imports Folic acid formulations from Greece due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Greek manufacturers offer products that meet international quality standards, which are essential for the Indian market's demand for specific Folic acid formulations not produced domestically. The expertise in producing such specialized products makes Greece a preferred sourcing destination for Indian pharmaceutical companies.

When compared to other origins like China, Germany, and the United States, Greece offers competitive advantages in terms of product quality and regulatory compliance. While China may offer lower prices, Greek products are often perceived as higher quality, which is crucial for pharmaceutical formulations. Germany and the United States also provide high-quality products but may have higher costs. Greece's unique advantage lies in its ability to offer specialized formulations at competitive prices while maintaining high-quality standards.

Indian importers face several supply chain risks when sourcing Folic acid formulations from Greece, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with multiple suppliers. Monitoring currency exchange rates and staying updated on regulatory changes in both countries are also essential to minimize potential disruptions.

1. 1Dual-Sourcing: Engage with multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain buffer stocks to manage lead times and potential shipping delays.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risks.
4. 4Supplier Qualification: Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities and review of quality certifications.
5. 5Regulatory Compliance: Stay informed about changes in import regulations and ensure all necessary documentation is in place to avoid customs delays.

Implementing these strategies can enhance the efficiency and reliability of sourcing Folic acid formulations from Greece